PERLES Plus

Underlying: Novartis SSPA/EUSIPA Product Type: Bonus Certificates (1320) SIX symbol: PNOVAU / Valor: 29185062 / ISIN: CH0291850623

Last update 13:19:54
  • Bid

    67.10 CHF
    Volume: 5'000

  • Ask

    67.60 CHF
    Volume: 5'000

Key figures

Strike absolute105.15 CHF
Strike116.00%
Participation100%
Spread0.50 CHF / 0.74%
Days to expiry982
Trading placeSIX SP Exchange
Settlementphysical

Tax information Switzerland

Withholding taxNo
Swiss income taxYes
EU savings taxNo
Stamp taxYes

Product calendar

Fixing date26.08.2015
Last trading date16.08.2019
Barrier touch dateNot touched
Expiry16.08.2019

Barrier information

Barrier absolute63.46 CHF
Distance barrier level1)8.49%
Barrier touchedNo

Cap information

Sideways return55.55% / 17.71% p.a.

SSPA risk figures

SSPA risk classHigh (5)
SSPA VaR15.79%
SSPA risk calculated on05.12.2016

UBS PERLES Plus

UBS PERLES Plus or Bonus Certificates offer you attractive yield opportunities even if the underlying asset (e.g. equity or index) does not significantly gain in value as expected, since UBS PERLES Plus enable you to improve yields in sideways markets depending on the product features in addition to the unlimited earnings opportunity. As an investor, you participate unconditionally 1:1 in a potential positive performance of the underlying asset. In exchange for the dividend of the underlying asset, UBS PERLES Plus offers you conditional partial protection, i.e. should the underlying asset never be listed at or below a predefined barrier (kick-out level) during the term, a minimum repayment is effected at maturity, which corresponds to the predefined PERLES Plus bonus level.

However, this partial protection ceases to apply if a barrier is broken during the term. According to this, PERLES Plus behaves like a normal PERLES, i.e. investors also participate in a negative performance of the underlying asset 1:1 without restriction, and so losses are likely. UBS PERLES Plus is thus suitable for investors with a medium to high risk preference. Investors must take the issuer risk into consideration, since loss of the invested capital could occur if UBS AG becomes insolvent, regardless of the performance of the underlying asset.

1) Prices are 15 Min. delayed